SCHEMBL5201380

SCHEMBL5201380

CCN1CCN(c2cccc3c2CCN(Cc2ccccc2)C3=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 8/20 0.54
DRD2 P14416 7/20 0.54
HTR6 P50406 3/20 0.54
HRH3 Q9Y5N1 1/20 0.54
DHPS P49366 1/20 0.52
HTT P42858 3/20 0.51
SMN1; SMN2 Q16637 6/20 0.50
LMNA P02545 5/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
DRD4 P21917 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PKM P14618 2/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 4/20 0.46
DRD1 P21728 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202887 0.83 DHPS (0.54) DRD3DRD2HTR6DHPSHTT
SCHEMBL4991491 0.75 DHPS (0.60) DHPSHTTSMN1; SMN2LMNAL3MBTL1
SCHEMBL3000762 0.75 DHPS (0.60) DHPSHTTSMN1; SMN2LMNAL3MBTL1
SCHEMBL2998761 0.74 DHPS (0.62) DHPSHTTSMN1; SMN2LMNAL3MBTL1
SCHEMBL8112183 0.73 UTS2R (0.55) KMT2AALDH1A1
SCHEMBL5812457 0.73 DHPS (0.58) DHPSHTTSMN1; SMN2LMNAL3MBTL1
SCHEMBL11096500 0.72 CHRNA7 (0.59) DRD3DRD2HTR6HRH3SMN1; SMN2
SCHEMBL27640867 0.71 DRD3 (0.47) DRD3DRD2HTR6HRH3L3MBTL1
SCHEMBL23952349 0.71 SMN1; SMN2 (0.89) DHPSHTTSMN1; SMN2LMNAL3MBTL1
SCHEMBL29657194 0.70 GRM5 (0.64) DRD3DRD2DHPSSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP claimed
EP-1601358-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-07 EP claimed
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC 2004-09-16 US claimed
WO-2004078176-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-16 WO claimed
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
EP-1601358-B1 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
US-7196088-B2 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC (US) 2007-03-27 US disclosed
EP-1601358-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-07 EP disclosed
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof ROCHE PALO ALTO LLC 2004-09-16 US disclosed
WO-2004078176-A1 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180874-A1 Substituted tetrahydroisoquinolines and uses thereof CYP3A5, CYP4X1, UGT1A1 DRD3 291/4885DRD2 401/4885HTR6 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.